# BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

> **NCT02379247** · PHASE1,PHASE2 · COMPLETED · sponsor: **Priyanka Sharma** · enrollment: 43 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** BYL-719 (alpelisib)
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT02379247
- **Lead sponsor:** Priyanka Sharma
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2017-09-21
- **Final completion:** 2022-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2022-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02379247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02379247, "BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02379247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*